Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

(2019) Antonis Fanouriakis et al.   ANNALS OF THE RHEUMATIC DISEASES

Novel paradigms in systemic lupus erythematosus

(2019) Thomas Dörner et al.   LANCET

TheSTAT4SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE

(2018) Niklas Hagberg et al.   ANNALS OF THE RHEUMATIC DISEASES

S3I-201 ameliorates tubulointerstitial lesion of the kidneys in MRL/lpr mice

(2018) Yunxia Du et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The regulation of JAKs in cytokine signaling and its breakdown in disease

(2018) Henrik M. Hammarén et al.   CYTOKINE

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

(2018) Daniel J Wallace et al.   LANCET

Baricitinib for systemic lupus erythematosus

(2018) Johanna Mucke et al.   LANCET

OUP accepted manuscript

(2018)   RHEUMATOLOGY

The Jakinibs in systemic lupus erythematosus: progress and prospects

(2018) Chi Chiu Mok   EXPERT OPINION ON INVESTIGATIONAL DRUGS

JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus

(2017) Anna Sophie Klaeschen et al.   EXPERIMENTAL DERMATOLOGY

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro

(2017) Kohei Murakami et al.   PLoS One

STAT3 Signaling in B Cells Is Critical for Germinal Center Maintenance and Contributes to the Pathogenesis of Murine Models of Lupus

(2016) Chuanlin Ding et al.   JOURNAL OF IMMUNOLOGY

JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus

(2016) Joerg Wenzel et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Therapeutic Potential for Targeting the Suppressor of Cytokine Signalling-1 Pathway for the Treatment of SLE

(2016) B. Sukka-Ganesh et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction

(2016) Yasuko Furumoto et al.   Arthritis & Rheumatology

Prion-like Aggregation of Mitochondrial Antiviral Signaling Protein in Lupus Patients Is Associated With Increased Levels of Type I Interferon

(2016) Wen-Hai Shao et al.   Arthritis & Rheumatology

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours

(2015) S J Thomas et al.   BRITISH JOURNAL OF CANCER

Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice

(2015) Lindsay J. Edwards et al.   CLINICAL IMMUNOLOGY

Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside

(2015) Yoshiya Tanaka   JOURNAL OF BIOCHEMISTRY

Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model

(2015) Emilie S. Chan et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

(2015) Ali Jabbari et al.   EBioMedicine

Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations

(2014) J. D. Milner et al.   BLOOD

SOCS signaling in autoimmune diseases: Molecular mechanisms and therapeutic implications

(2014) Yan Liang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Prevention of Murine Lupus Nephritis by Targeting Multiple Signaling Axes and Oxidative Stress Using a Synthetic Triterpenoid

(2014) Tianfu Wu et al.   Arthritis & Rheumatology

Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome

(2013) Gulbu Uzel et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

(2013) L. Van Rompaey et al.   JOURNAL OF IMMUNOLOGY

JAK2 inhibition in murine systemic lupus erythematosus

(2012) Clement Tagoe et al.   Immunotherapy

JAK/STAT signaling in hematological malignancies

(2012) W Vainchenker et al.   ONCOGENE

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells

(2011) Keisuke Maeshima et al.   ARTHRITIS AND RHEUMATISM

Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

(2011) L. D. Lu et al.   JOURNAL OF IMMUNOLOGY

Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus

(2011) M Kawasaki et al.   LUPUS

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice

(2010) S. Wang et al.   LUPUS

A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F)

(2009) Lequn Zhao et al.   BIOCHEMICAL JOURNAL

Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis

(2008) T. Arakawa et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Paradigm shifts in the cell biology of STAT signaling

(2008) Pravin B. Sehgal   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY